APPENDIX TO PRESS RELEASE DD 15 MARCH 2007

Fornix BioSciences N.V.

CONSOLIDATED INCOME STATEMENT (in euros)
For the financial year from 1 January 2006 to 31 December 2006
With comparative figures for the 2005 financial year

	2006 Continued business-activities	2006[1)] Discontinued business-activities	2006 Total	2005 Continued business-activities	2005 Discontinued business-activities	2005 Total
Income	95,982,353	1,943	95,984,296	87,690,063	50,013	87,740,076
Cost of sales	64,060,092	393	64,060,485	60,212,125	197,379	60,409,504
Gross result	**31,992,261**	**1,550**	**31,923,811**	**27,477,938**	**(147,366)**	**27,330,572**
Other Income	**43,576**	**587,915**	**631,491**	**28,691**	**-**	**28,691**
Distribution costs	1,423,616	-	1,423,616	1,336,520	113,058	1,449,578
Personnel costs	6,926,404	-	6,926,404	6,230,198	413,307	6,643,505
Travel expenses	1,140,880	-	1,140,880	964,108	99,001	1,063,109
Depreciation and amortisation	700,204	(9,545)	690,659	775,451	115,990	891,441
Accommodation	275,031	-	275,031	237,892	39,692	277,584
Research and development	2,962,204	31,888	2,994,092	634,239	214,719	848,958
Quality control costs	517,141	-	517,141	436,250	9,800	446,050
Production and warehouse costs	152,579	-	152,579	143,225	-	143,225
General overheads	3,166,866	57,566	3,224,432	2,932,939	244,847	3,177,786
Charged on to production and trading inventories	(1,400,000)	-	(1,400,000)	(1,445,000)	-	(1,445,000)
Sum of the costs	**15,864,925**	**79,909**	**15,944,834**	**12,245,822**	**1,250,414**	**13,496,236**
Result from operating activities	**16,100,912**	**509,556**	**16,610,468**	**15,260,807**	**(1,397,780)**	**13,863,027**
Net financing income/expenses	438,376	8	438,384	608,980	(157,780)	451,200
Profit before taxation	**16,539,288**	**509,564**	**17,048,852**	**15,869,787**	**(1,555,560)**	**14,314,227**
Tax on profits	4,536,894	65,476	4,602,370	5,078,578	(497,803)	4,580,775
Profit for the financial year	**12,002,394**	**444,088**	**12,446,482**	**10,791,209**	**(1,057,757)**	**9,733,452**

	2006 Continued business-activities	2006 [1] Discontinued business-activities	2006 Total	2005 Continued business-activities	2005 Discontinued business-activities	2005 Total
Attributable to:						
Shareholders of the						
Parent company	12,002,394	443,468	12,445,862	10,791,209	(1,057,922)	9,733,287
Minority interest	-	620	620	-	165	165
Profit for the financial year	**12,002,394**	**444,088**	**12,446,482**	**10,791,209**	**(1,057,757)**	**9,733,452**
Ordinary earnings per share	1.81	0.07	1.88	1.69	(0.16)	1.53
Diluted earnings per share	1.80	0.06	1.86	1.66	(0.16)	1.50

[1] The 2006 justified discontinued business activities are the result of the decision taken at the end of the financial year 2005 to discontinue the divisions Theranostics and R&D.

CONSOLIDATED SUMMARY OF TOTAL RESULT (in euros)
For the financial year from 1 January 2006 to 31 December 2006
With comparative figures for the 2005 financial year

	2006	**2005**
Exercise of staff options	511,953	1,229,651
Net profit directly accounted for in the shareholders' equity	**511,953**	**1,229,651**
Profit for the financial year	12,446,482	9,733,452
Total result for the financial year	**12,958,435**	**10,963,103**
Attributable to:		
Shareholders of the parent Company	12,957,815	10,962,938
Minority interest	620	165
Total result for the financial year	**12,958,435**	**10,963,103**

CONSOLIDATED BALANCE SHEET (in euros)
(before allocation of the result)
As at 31 December 2006 with comparative figures as at 31 December 2005

	31 December 2006	31 December 2005
ASSETS		
Non-current assets		
Intangible assets	11,647,719	300,469
Property, plant and equipment	4,026,278	2,548,112
Deferred tax assets	188,585	169,779
Total Non-current assets	**15,862,582**	**3,018,360**
Current assets		
Inventories	9,490,031	8,689,211
Trade and other receivables	10,953,623	8,946,789
Cash and cash equivalents	20,749,318	22,660,619
Total Current assets	**41,192,972**	**40,296,619**
Total Assets	**57,055,554**	**43,314,979**
LIABILITIES AND EQUITY		
Shareholders' equity		
Paid-up and called-up share capital	1,041,010	1,004,766
Share premium	20,340,298	15,259,919
Other reserves	6,678,069	4,488,905
Profit for the financial year	12,445,862	9,733,287
Total Shareholders' equity attributable to shareholders of the parent Company	**40,505,239**	**30,486,877**
Minority interest	906	286
Total Shareholders' equity	**40,506,145**	**30,487,163**
Non-current liabilities		
Interest-bearing loans and other non-current financing obligations	-	159,468
Employee benefits	364,067	445,885
Provisions	-	1,037,990
Deferred tax liabilities	270,707	-
Total Non-current liabilities	**634,774**	**1,643,343**
Current liabilities		
Provisions	263,016	-
Interest-bearing loans and other current financing obligations	-	609,986
Trade payables	7,201,904	2,983,154
Taxes payable	709,205	1,980,136
Other items to be paid	7,740,510	5,611,197
Total Current liabilities	**15,914,635**	**11,184,473**
Total Liabilities and equity	**57,055,554**	**43,314,979**

CONSOLIDATED CASH FLOW STATEMENT (in euros)
For the financial year from 1 January 2006 to 31 December 2006
With comparative figures for the 2005 financial year

		2006		**2005**
Cash flow from operating activities				
Receipts from customers	100,232,851		94,828,508	
Payments to suppliers and employees	(81,752,931)		(79,792,923)	
Net cash flow from business operations		18,479,920		15,035,585
Interest received	466,388		179,268	
Interest paid	(95,996)		(17,618)	
Tax paid on profits	(6,702,779)		(4,106,882)	
Grants received	65,358		48,691	
Cash flow from other operating activities		(6,267,029)		(3,896,541)
Net cash flow from operating activities		**12,212,891**		**11,139,044**
Cash flow from investing activities				
Acquisition of subsidiaries	(9,935,454)		-	
Investments in intangible assets	(159,636)		(194,405)	
Divestments in intangible assets	100,000		-	
Investments in property, plant and equipment	(757,267)		(242,066)	
Divestment in subsidiaries	200,000		-	
Divestment in property, plant and equipment	24,469		-	
Net cash flow from investing activities		**(10,527,888)**		**(436,471)**
Cash flow from financing activities				
Repayment of interest-bearing loans	(935,281)		(17,392)	
Earnings from exercise of staff options	511,953		1,229,651	
Dividend paid	(3,148,618)		(2,413,520)	
Net cash flow from financing activities		**(3,571,946)**		**(1,201,261)**
Net increase / decrease in cash and cash equivalents		**(1,886,943)**		**9,501,312**
Cash and cash equivalents as at 1 January		22,660,619		13,159,307
Cash acquired subsidiaries		(24,358)		-
Cash and cash equivalents as at 31 December		**20,749,318**		**22,660,619**

CHANGES IN SHAREHOLDERS' EQUITY (in euros)

Balance as at 1 January 2005	**21,884,900**
Dividend payment 2004	(1,316,881)
Interim dividend 2005	(1,096,639)
Profit for 2005 financial year	9,733,287
Exercise of personnel options	1,229,651
Cost of share ownership plan 2005	52,559
Balance as at 31 December 2005	**30,486,877**
Dividend payment 2005	(1,495,708)
Interim dividend 2006	(1,652,910)
Profit for 2006 financial year	12,445,862
Exercise of personnel options	511,953
Cost of share ownership plan 2006	209,165
Balance as at 31 December 2006	**40,505,239**

Notes

1 General

The financial data as reported in this press release are an excerpt from the annual accounts of Fornix BioSciences N.V. but do not represent the full annual accounts. The Company's consolidated annual accounts for 2006 include the Company and its subsidiaries (together referred to as the "Group").

The annual report and annual accounts were discussed in the supervisory Board meeting of 13 March 2007 and will be submitted to the Annual General Meeting of shareholders for adoption on 20 April 2007. The auditors of Fornix BioSciences N.V. have issued an unqualified opinion on these annual accounts..

Publication of the annual accounts 2006 will take place on 20 April 2007.

2 Statement of compliance

The annual accounts 2006 have been prepared in accordance with International Financial Reporting Standards (IFRS), as adopted by the European Union.

3 Basis of preparation

The preparation of the annual accounts requires the management of the Company to form opinions and to make estimates and assumptions that influence the application of policies and the reported values of assets and liabilities and of income and expenses. The actual outcomes may differ from these estimates.

With effect from 2005 the Group reports according to IFRS. For the year 2006 no important changes occurred with regard to the accounting principles of the Group.